FullCircle Wealth’s Pyxis Oncology PYXS Stock Holding History

FullCircle Wealth’s Portfolio PYXS Stock Details PYXS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-13,660	Closed	-$51.8K	–	234
2024 Q3	$51.8K	Buy	13,660 +1,660	+14%	+$5.81K	0.02%	185
2024 Q2	$45.2K	Buy	+12,000	New	+$50.5K	0.02%	167

Other funds holding PYXS

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

FullCircle Wealth's PYXS Position: Q4 2024 in Review

FullCircle Wealth sold out of Pyxis Oncology (PYXS) in Q4 2024, closing a stake of 13,660 shares — an estimated $51.8K sold.

FullCircle Wealth first reported a position in PYXS in Q2 2024 and held it in 2 quarters. The position peaked at $51.8K in Q3 2024. 99 funds tracked by Wall St. Rank hold PYXS as of Q4 2024.

FullCircle Wealth reported no remaining Pyxis Oncology position as of Q4 2024 after selling out during the quarter.
FullCircle Wealth sold 13,660 Pyxis Oncology shares in Q4 2024, an estimated $51.8K.
FullCircle Wealth first reported a position in Pyxis Oncology in Q2 2024 and held it in 2 quarters.
FullCircle Wealth's Pyxis Oncology position peaked at $51.8K in Q3 2024.
99 funds tracked by Wall St. Rank held Pyxis Oncology as of Q4 2024.

Based on FullCircle Wealth's 13F filing for Q4 2024, filed 14 Feb 2025.